Search

Displaying results 751 - 760 of 10000 in total
  1. Drug

    Potassium perchlorate

    go.drugbank.com/drugs/DB09418
    ApprovedWithdrawn

    The use of potassium perchlorate as a component in sealing gaskets for food containers has been revoked by the FDA following the use being abandoned by the industry [L2365]. … Potassium perchlorate acts as a competitive inhibitor of iodine uptake by the thyroid gland and attenuates the production of the thyroid hormone.

  2. Drug

    Tamsulosin

    go.drugbank.com/drugs/DB00706
    ApprovedInvestigational

    [A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238]

    Products: Nb-tamsulosin CR
  3. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    [A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity. … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]

    Synonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDECategories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  4. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases. … [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023.

  5. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    One minor metabolite, the isoprene, has the same potency as its parent compound. … Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

  6. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722]. … The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent

  7. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    are currently not properly understood. … This action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects

  8. Drug

    Atezolizumab

    go.drugbank.com/drugs/DB11595
    ApprovedInvestigational

    [A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.

  9. Drug

    Bicalutamide

    go.drugbank.com/drugs/DB01128
    ApprovedInvestigational

    Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers.

    Categories: Antiandrogens, non-steroidalProducts: Nu-bicalutamide
  10. Drug

    Camphor

    go.drugbank.com/drugs/DB01744
    ApprovedInvestigationalWithdrawn

    The FDA ruled that camphorated oil could not be marketed in the United States and that no product could contain a concentration higher than 11%.

    Mixtures: Delsym No Mess Vapor Roll On, Zam-Buk Ointment